|
1.
|
|
18 p, 3.8 MB |
Integrative epigenomics in Sjögren's syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature
/
Teruel, María (Universidad de Granada) ;
Barturen, Guillermo (Universidad de Granada) ;
Martínez-Bueno, Manuel (Universidad de Granada) ;
Castellini-Pérez, Olivia (Universidad de Granada) ;
Barroso-Gil, Miguel (Universidad de Granada) ;
Povedano, Elena (Universidad de Granada) ;
Kerick, Martin (Consejo Superior de Investigaciones Científicas) ;
Català-Moll, Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Makowska, Zuzanna (Bayer Pharma) ;
Buttgereit, Anne (Bayer Pharma) ;
Beretta, Lorenzo (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano) ;
Vigone, Barbara (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano) ;
Pers, Jacques Olivier (Hospital de la Cavale Blanche) ;
Saraux, Alain (Hospital de la Cavale Blanche) ;
Devauchelle-Pensec, Valérie (Hospital de la Cavale Blanche) ;
Cornec, Divi (Hospital de la Cavale Blanche) ;
Jousse-Joulin, Sandrine (Hospital de la Cavale Blanche) ;
Lauwerys, Bernard (Université catholique de Louvain) ;
Ducreux, Julie (Université Catholique de Louvain) ;
Maudoux, Anne Lise (Université catholique de Louvain) ;
Vasconcelos, Carlos (Centro Hospitalar do Porto) ;
Tavares, Ana (Centro Hospitalar do Porto) ;
Neves, Esmeralda (Centro Hospitalar e Universitário do Porto) ;
Faria, Raquel (Centro Hospitalar do Porto) ;
Brandão, Mariana (Centro Hospitalar do Porto) ;
Campar, Ana (Centro Hospitalar do Porto) ;
Marinho, António (Centro Hospitalar do Porto) ;
Farinha, Fátima (Centro Hospitalar do Porto) ;
Almeida, Isabel (Centro Hospitalar do Porto) ;
Gozalez-Gay Mantecón, Miguel Angel (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Blanco, Ricardo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Corrales Martínez, Alfonso (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Cervera, Ricard (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rodríguez-Pintó, Ignasi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Espinosa, Gerard (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lories, Rik (Katholieke Universiteit Leuven) ;
De Langhe, Ellen (University Hospitals Leuven (Bèlgica)) ;
Hunzelmann, Nicolas (Klinikum der Universitaet zu Koeln) ;
Belz, Doreen (Klinikum der Universitaet zu Koeln) ;
Witte, Torsten (Medical University Hannover) ;
Baerlecken, Niklas (Medizinische Hochschule Hannover) ;
Stummvoll, Georg (Medical University Vienna) ;
Zauner, Michael (Medical University Vienna) ;
Lehner, Michaela (Medical University Vienna) ;
Collantes Estevéz, Eduardo (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Ortega-Castro, Rafaela (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Aguirre, Mª Angeles (Hospital Universitario "Reina Sofía" (Còrdova, Espanya)) ;
Escudero-Contreras, Alejandro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Castro-Villegas, Ma Carmen (Hospital Universitario San Cecilio (Granada)) ;
Ortego, Norberto (Complejo Hospitalario Universitario de Granada) ;
Fernández Roldán, María Concepción (Complejo Hospitalario Universitario de Granada) ;
Raya, Enrique (Complejo Hospitalario Universitario de Granada) ;
Jiménez Moleón, Inmaculada (Complejo Hospitalario Universitario de Granada) ;
de Ramon, Enrique (Hospital Regional Universitario de Málaga) ;
Díaz Quintero, Isabel (Hospital Regional Universitario de Málaga) ;
Meroni, Pier Luigi (Università degli studi di Milano) ;
Gerosa, Maria (Università degli studi di Milano) ;
Schioppo, Tommaso (Università degli studi di Milano) ;
Artusi, Carolina (Università degli studi di Milano) ;
Chizzolini, Carlo (University Hospital and School of Medicine) ;
Zuber, Aleksandra (Hospitaux Universitaires de Genève) ;
Wynar, Donatienne (Hospitaux Universitaires de Genève) ;
Kovács, Laszló (University of Szeged) ;
Balog, Attila (University of Szeged) ;
Deák, Magdolna (University of Szeged) ;
Bocskai, Márta (University of Szeged) ;
Dulic, Sonja (University of Szeged) ;
Kádár, Gabriella (University of Szeged) ;
Hiepe, Falk (Charite) ;
Gerl, Velia (Charité University Hospital) ;
Thiel, Silvia (Charité University Hospital) ;
Rodriguez Maresca, Manuel (Andalusian Public Health System Biobank) ;
López-Berrio, Antonio (Andalusian Public Health System Biobank) ;
Aguilar-Quesada, Rocío (Andalusian Public Health System Biobank) ;
Navarro-Linares, Héctor (Andalusian Public Health System Biobank) ;
Álvarez, Montserrat (Immunology and Allergy. University Hospital and School of Medicine) ;
Alvarez‑Errico, Damiana (Institut d'Investigació Biomèdica de Bellvitge) ;
Azevedo, Nancy (Centro Hospitalar e Universitário do Porto) ;
Barbarroja, Nuria (Bayer Pharma) ;
Buttgereit, Anne (Bayer Pharma) ;
Cheng, Qingyu (Charité University Hospital) ;
Chizzolini, Carlo (University Hospital and School of Medicine) ;
Cremer, Jonathan (KU Leuven) ;
De Groof, Aurélie (Université Catholique de Louvain) ;
De Langhe, Ellen (University Hospitals Leuven (Bèlgica)) ;
Ducreux, Julie (Université Catholique de Louvain) ;
Dufour, Aleksandra (University Hospital and School of Medicine) ;
Gerl, Velia (Charité University Hospital) ;
Hernandez‑Fuentes, Maria (UCB) ;
Khodadadi, Laleh (Charité University Hospital) ;
Kniesch, Katja (Medical University Hannover) ;
Li, Tianlu (Charité University Hospital) ;
Lopez‑Pedrera, Chary (Université Catholique de Louvain) ;
Makowska, Zuzanna (Bayer Pharma) ;
Marañón, Concepción (Universidad de Granada) ;
Muchmore, Brian (Universidad de Granada) ;
Neves, Esmeralda (Centro Hospitalar e Universitário do Porto) ;
Rouvière, Bénédicte (University of Brest) ;
Simon, Quentin (University of Brest) ;
Trombetta, Elena (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano) ;
Varela, Nieves (Medical University Hannover) ;
Witte, Torsten (Medical University Hannover) ;
Pers, Jacques Olivier (Hospital de la Cavale Blanche) ;
Marañón, Concepción (Universidad de Granada) ;
Ballestar, Esteban (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martin, Javier (Consejo Superior de Investigaciones Científicas) ;
Carnero-Montoro, Elena (Universidad de Granada) ;
Alarcón-Riquelme, Marta E (Karolinska Institutet (Estocolm, Suècia)) ;
Universitat Autònoma de Barcelona
Primary Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration and damage of exocrine salivary and lacrimal glands. The etiology of SS is complex with environmental triggers and genetic factors involved. [...]
2021 -  10.1038/s41598-021-01324-0
Scientific reports, Vol. 11 Núm. 1 (december 2021) , p. 23292
|
|
|
3.
|
|
11 p, 779.0 KB |
Antitubercular drugs for an old target : GSK693 as a promising InhA direct inhibitor
/
Martínez-Hoyos, María (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Perez-Herran, Esther (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Gulten, Gulcin (Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA) ;
Encinas, Lourdes (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Álvarez-Gómez, Daniel (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Alvarez, Emilio (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ferrer-Bazaga, Santiago (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
García-Pérez, Adolfo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ortega, Fátima (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Angulo-Barturen, Iñigo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Rullas-Trincado, Joaquin (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Blanco Ruano, Delia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Torres, Pedro (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Castañeda, Pablo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Huss, Sophie (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Fernández Menéndez, Raquel (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
González del Valle, Silvia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ballell, Lluis (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Barros, David (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Modha, Sundip (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
Dhar, Neeraj (School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne 1015, Switzerland) ;
Signorino-Gelo, François (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
McKinney, John D. (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
García-Bustos, Jose Francisco (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Lavandera, Jose Luis (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Sacchettini, James C. (Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA) ;
Jimenez, M. Soledad (Instituto de Salud Carlos III) ;
Martín-Casabona, Nuria (Hospital Universitari Vall d'Hebron) ;
Castro-Pichel, Julia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Mendoza-Losana, Alfonso (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Universitat Autònoma de Barcelona
Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. [...]
2016 - 10.1016/j.ebiom.2016.05.006
EBioMedicine, Vol. 8 (may 2016) , p. 291-301
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
